Latest Period
Q1 2026
Security Snapshot
NRX PHARMACEUTICALS INC - COM NEW Institutional Ownership
CUSIP: 629444209
13F Institutional Holders and Ownership History from Q2 2024 to Q1 2026
Institutions Reporting
1
Shares (Excl. Options)
34,479
Price
$2.97
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COM NEW
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 34,479
- Total 13F value
- $102,403
- Share change
- 0
- Number of holders
- 1
- SEC-reported price per share
- $2.97
Latest holder snapshot
2 signals
Issuer context
Names, identifiers, and filing context for this profile.
1 identity field
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- 629444209 - NRX PHARMACEUTICALS INC - COM NEW is tracked under CUSIP 629444209.
- 1 institution reported positions in Q1 2026.
- Schedule 13D/13G significant owner rows are not currently available.
Change
- Holder count moved from 2 to 1 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $2,213,598 to $102,403.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 1 institution filings for Q1 2026.
Security key
629444209
Latest holder period
Q1 2026
13F holders
1
13D/G owners
0
CIK / CUSIP context first
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 629444209:
As of 31 Mar 2026, 1 institutional investors reported holding 34,479 shares of NRX PHARMACEUTICALS INC - COM NEW.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
4
Latest
Q1 2026
Rows shown
1-4 of 4